PF 4967544Alternative Names: PF-04967544; PF4967544
Latest Information Update: 01 Jun 2011
At a glance
- Originator Pfizer
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Renal failure
Most Recent Events
- 27 Sep 2010 Phase-I development is ongoing
- 27 Jan 2010 Phase-I clinical trials in Renal failure in USA (unspecified route)